Bewe, a digital health company based at Biopôle, has been awarded the Pfizer Research Prize 2026 in the Digital Health category. This prestigious distinction recognizes outstanding scientific achievements that significantly advance medical innovation in Switzerland, highlighting Bewe’s contribution to addressing one of today’s major public health challenges.
The company was recognized for its clinically validated digital therapeutic designed to reduce unhealthy cravings and overeating behaviors. By combining neuroscience, artificial intelligence, and gamification, Bewe’s solution works to recalibrate the brain’s reward system through engaging cognitive training delivered via a mobile app. This innovative approach enables behavioral change without relying on medication or willpower alone, offering a new pathway for managing obesity and related conditions.
